Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience

CNS Oncol. 2020 Sep 1;9(3):CNS60. doi: 10.2217/cns-2020-0010. Epub 2020 Sep 18.

Abstract

Aim: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. Materials & Methods: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. Results: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. Conclusion: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.

Keywords: 3D-conformal radiotherapy (3D-CRT); adjuvant TMZ; cochlea; concurrent temozolomide (TMZ); conformity index; dose spillage; dosimetric analysis; homogeneity index; optic chiasm; postoperative glioblastoma (GBM).

MeSH terms

  • Antineoplastic Agents, Alkylating / therapeutic use
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy*
  • Chemoradiotherapy
  • Female
  • Glioblastoma / diagnostic imaging
  • Glioblastoma / drug therapy
  • Glioblastoma / pathology
  • Glioblastoma / radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Organs at Risk / diagnostic imaging
  • Organs at Risk / radiation effects*
  • Prognosis
  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted / methods*
  • Radiotherapy, Conformal
  • Radiotherapy, Intensity-Modulated
  • Retrospective Studies
  • Temozolomide / therapeutic use
  • Tertiary Care Centers

Substances

  • Antineoplastic Agents, Alkylating
  • Temozolomide